Department of Pathology, Loyola University Medical Center, Maywood, IL.
Adv Anat Pathol. 2013 Nov;20(6):424-39. doi: 10.1097/PAP.0b013e3182a92dc3.
The amyloidoses comprise a group of disorders of diverse etiology, in which different proteins undergo abnormal folding, leading to their deposition in tissues and concomitant tissue toxicity. This process ultimately leads to tissue destruction, with organ failure and progressive disease. Recent progress in the treatment of the systemic amyloidoses has dramatically changed the outlook for affected patients and their families. From a relatively rare and esoteric disorder that was typically diagnosed only at autopsy, or was invariably fatal if diagnosed during life, it has now become a disease for which, with modern therapies, durable responses and long-term survival can be achieved. The clinical symptoms are largely nonspecific, and therefore misdiagnosis, or late diagnosis, have been major detriments in achieving better treatment outcomes. Despite advances in laboratory medicine, amyloidoses are still diagnosed on the basis of the pathologic detection of deposits in tissues. Thus, effective primary screening for these diseases requires the active engagement of the pathology community at large, while specialized laboratories and treatment centers can offer secondary consultation and assistance with further steps. This review provides an update on pathogenesis, the clinical and pathologic features, and treatments of various amyloidoses, as well as the current terminology, classification, and practical considerations that are relevant to the diagnosis.
淀粉样变包括一组病因不同的疾病,其中不同的蛋白质发生异常折叠,导致其在组织中沉积并伴随组织毒性。这一过程最终导致组织破坏、器官衰竭和进行性疾病。系统性淀粉样变治疗的最新进展显著改变了受影响患者及其家庭的前景。从一种相对罕见和深奥的疾病,通常仅在尸检时诊断,或在生前诊断时总是致命的,现在已经成为一种可以通过现代治疗方法实现持久反应和长期生存的疾病。临床症状在很大程度上是非特异性的,因此误诊或晚期诊断一直是实现更好治疗结果的主要障碍。尽管实验室医学取得了进展,但淀粉样变仍基于组织中沉积物的病理检测进行诊断。因此,对这些疾病进行有效的初步筛查需要广大病理学界的积极参与,而专门的实验室和治疗中心可以提供二级咨询和进一步步骤的协助。这篇综述提供了对各种淀粉样变的发病机制、临床和病理特征以及治疗的最新更新,以及与诊断相关的当前术语、分类和实际考虑。